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Final discussion and future perspectives
Summary
Fetal megacystis and congenital LUTO are severe conditions with challenging diagnostic 
work-up and controversial antenatal management (1)(2)(3)(4). In the previous chapters, 
we have reported in detail the results of a retrospective multicenter national study and 
a cross-sectional prospective study, with the main aim of providing clinicians with robust 
data regarding the differential diagnosis and management of fetal megacystis and LUTO. 
In summary, we firstly focused on the definition and differential diagnosis of megacystis 
(part 1); secondly, we aimed at optimizing patient selection in cases with isolated LUTO, 
theoretically eligible for antenatal intervention (part 2); finally, we concentrated on the 
antenatal prediction of prognosis in LUTO, both in terms of survival and postnatal renal 
function (part 3). In this last chapter, we provide a general overview of our results and 
present three management algorithms (figure 1, 2 and 3), developed on the base of our 
findings. To conclude, future perspectives and limitations of this thesis will be discussed. 
From fetal megacystis to LUtO
The suspicion of LUTO typically arises from the evidence of an enlarged fetal bladder, 
also known as megacystis (1)(2). However, whenever faced with either early (diagnosed 
before or at the 17th week of gestation) or late megacystis (diagnosed after the 17th week of 
gestation), a number of underlying conditions and associated structural anomalies need to 
be considered and excluded (2)(6). 
In chapter 3, the etiologies of megacystis were investigated and in 33% of cases an 
underlying chromosomal abnormality, genetic syndrome or developmental anomaly cases 
was found. Fetal medicine specialists should be aware that fetal megacystis may appear as a 
corollary finding of an underlying genetic disorder and that associated structural anomalies 
can be detected in 30-34% of cases (chapter 3)(2)(6)(7). 
At the light of this evidence, as shown in figure 1 and 2, we recommend to perform 
a detailed ultrasound scan, with special attention for the spine, skeleton and hear. It is 
also crucial to verify fetal sex as early as possible, since female fetuses carry a much worse 
prognosis, due to the common involvement of other abnormally developed organs. 
Moreover, amniocentesis or chorionic villus sampling (CVS) with QF-PCR should be offered 
more liberally in view of the well-known association between megacystis and chromosomal 
abnormalities, of which trisomy18 is the most frequent. Furthermore, in case of negative 
QF-PCR result and depending on the detected structural anomalies, arrays CHG and even 
prenatal WES or fetal MRI may be considered. 










 weeks’ gestation) 
Detailed ultrasound examination with full anatomic survey 
 + karyotyping (QF-PCR with fetal sex) 
Presence of associated  
anomalies 
Absence of associated  
anomalies 
Consider further investigations 
(array CHG, fetal MRI) for 
excluding:  
 ANM, cloacal anomalies  
 VACTERL association 
 OEIS and CRS 
Measure LBD 
LBD > 12 mm LBD ≤ 12 mm 
Repeat weekly US scan 
















See next flowchart (figure 3) 
Figure 1. Clinical algorithm to guide fetal specialists in the diagnostic work-up and management of 
early megacystis. 
NT, nuchal translucency; LBD longitudinal bladder diameter; MRI, magnetic resonance imaging; UA, urethral 
atresia; PUV, posterior urethral valves; MMIHS, megacystis microcolon intestinal hypoperistalsis syndrome.
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Figure 2. Clinical algorithm to guide fetal specialists in the diagnostic work-up and management of 
late megacystis.
LBD longitudinal bladder diameter; MRI, magnetic resonance imaging; VUR, vesicoureteral reflux; MMIHS, 
megacystis microcolon intestinal hypoperistalsis syndrome.
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can in fact provide better imaging of fetal anatomy in case of severe oligo- or anhydramnios 
or suspicion of an anorectal malformation (8)(9). Array CHG should be in particular offered 
when heart defects are detected in order to exclude a 22q11 deletion syndrome (chapter 
3)(10)(11).Other miscellaneous non-classic chromosomal abnormalities (e.g. duplication 
19q13.33; deletion 5q.35.2; etc.) can be detected by array CGH in fetuses with isolated 
megacystis, however their clinical significance is uncertain for most of them (chapter 3).
Once complex megacystis and associated anomalies have been ruled out, the possibility 
of spontaneous resolution should be considered (12). From chapter 4, it can be inferred 
that the LBD measurement can reliably estimate the chance of resolution. In particular, the 
bladder enlargement will spontaneously regress in 70% of fetuses with early megacystis 
and LBD ≤12 mm (chapter 4), and cases of megacystis resolving before 23weeks’ gestation 
have generally a favorable outcome without major urological sequelae. The underlying 
cause for this transitory bladder enlargement may be sought, as previously suggested, in 
the immaturity of autonomic innervation and smooth muscle fibers in early gestation (12). 
antenatal diagnosis of LUtO and eligibility for fetal therapy
In order to offer parents appropriate therapeutic options for LUTO and avoid meaningless 
interventions, only cases theoretically eligible for antenatal intervention should be selected 
(13). Although this concept may seem trivial and the diagnosis of LUTO may be considered 
straightforward, previous studies have highlighted that one third of all prenatally suspected 
LUTO are reclassified postnatally, with the majority of them reclassified to vesico-ureteral 
reflux (VUR)(14). Such cases would not benefit from in utero treatment and need to be 
identified prenatally (13). 
In chapter 5, we investigated the best antenatal criteria for identifying, among fetuses with 
early megacystis, those with isolated posterior urethral valves (PUV), theoretically eligible for 
early fetal treatment. This approach demonstrated good accuracy with a sensitivity of 82% 
and a specificity of 68% (chapter 4). As shown in figure 1, we also found that the finding of 
an associated umbilical cord cyst (UCC) carried a high risk of urethral atresia (OR 15; p=0.3), 
which is an unfavorable form of LUTO, not eligible for early fetal cystoscopy (chapter 4). This 
finding confirms the hypothesis of Sepulveda et al., who speculated that an abnormally 
distended bladder may prevent the closure of the allantois in the first stages of life, when 
bladder is connected with the umbilical cord (15)(16), and may eventually lead to a cystic 
dilatation of the umbilical cord. This is more likely to occur in fetuses with an early and 
severe bladder enlargement, as it is the case in the setting of urethral atresia (17)(chapter 5). 
As shown in the second algorithm in figure 2, a standardized US approach with the 
assessment of bladder volume, ureters, amniotic fluid (AF) amount and fetal gender, should 
9137
Final discussion and future perspectives
be carried out in fetuses with late megacystis. This recommendation originates from our 
findings in chapter 6, where the optimal combination of US parameters for diagnosing LUTO 
has been investigated (chapter 6). The assessment of these five antenatal parameters, and 
their combination in a clinical score, showed good discriminative capacity for predicting 
LUTO and reducing the number of false positive diagnoses (chapter 6). However, an external 
validation of these results is essential before endorsing this statement and supporting its 
clinical applicability. 
Clinical heterogeneity and underlying pathophysiology of LUtO
In fetuses highly suspected for isolated LUTO, antenatal counseling and management 
should be individualized on the base of the expected outcome. This is made problematic 
by the highly variable natural history and outcome of LUTO. In fact, severe forms of LUTO 
can lead to early and massive bladder distention, renal dysplasia, oligohydramnios, and 
eventual soft tissue deformities (Potter sequence) (18)(19). Conversely, fetuses with milder 
forms of LUTO can even preserve normal AF amount throughout pregnancy and favorable 
renal function after birth (20). This heterogeneity in the clinical presentation of LUTO can 
be partially explained by two factors: the type of obstruction, and the reaction to the 
obstructive insult, with the occasional occurrence of a pressure ‘pop-off’ mechanism.
The term LUTO refers to a heterogeneous group of anatomical defects, that includes 
urethral atresia, urethral valves and urethral stenosis. Urethral atresia (UA), defined as 
complete infravesical obstruction that obliterates the distalmost portion of the prostatic 
urethra, represents the most severe form of LUTO with very poor prognosis (21). Urethral 
stenosis constitutes a less common and less severe variant of UA and presents with 
narrowing of the urethral lumen. Urethral valves can be distinguished in anterior urethral 
valves (AUV), caused by a mucosal fold arising from the floor of the urethra (22)(23), and 
posterior urethral valves (PUV), that constitute the most common cause of LUTO with a 
birth prevalence of 1 to 2 per 10,000 live male births (24)(25). Three types of PUV have 
been described by Hugh Hampton Young (26)(27). Type I valves are the most frequent 
and appear as leaflets originating from verumontanum and extending in an inferior and 
anterior direction. Type II valves are not obstructive and represent mucosal folds extending 
superiorly from the verumontanum to the bladder neck. Type III valves appear as an annular 
ring or membrane in the posterior urethra (26). 
Irrespective of obstruction type, LUTO can progress differently case per case: with 
megacystis or bladder wall fibrosis, with unilateral or bilateral hydronephrosis, with renal 
dysplasia or severe vesicoureteral reflux (28). This clinical heterogeneity can be partially 
explained also by the occurrence of a number of “pop-off” mechanisms, developed as 
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response to the increased intraluminal pressure within the urinary tract. Pop-off mechanisms 
could protect the urinary system from the deleterious effects of elevated bladder pressure 
by allowing urine to extravasate: into the peritoneal cavity (urinary ascites), within the 
perirenal space or retroperitoneum (urinomas) or in the umbilical cord (umbilical cord cyst 
and patent urachus). Another pop-off mechanisms is represented by the cystic dilatation of 
the ureter (ureterocele), that in some cases can expand into the bladder and obstruct the 
urine outflow, thus constituting a non-classic and infrequent cause of LUTO (obstructive 
ureterocele) (26). The development of bladder diverticula or unilateral vesico-ureteral reflux 
have been also defined as pop-off mechanisms (29)(30).
To date, antenatal pop-off mechanisms of LUTO have been little studied and their role 
in terms of perinatal and long-term outcome has not been yet elucidated. It still not clear 
whether they could protect the urinary system from the deleterious effects of an elevated 
vesical pressure or they could rather indicate the presence of a severe insult that will anyway 
entail bladder and urinary dysfunctions later in life (30). Hereby in Table1, we report on the 
incidence of some of these pop-off mechanisms in our retrospective cohort.
table 1. Incidence and GA at diagnosis in fetuses developing or not a pop-off mechanism. 
Incidence GA at diagnosis of megacystis
Urinary Ascites 41 (8%) 20 ±6
UCC 41 (8%)  16 ±6*
Urinomas/ureterocele 27 (5%) 24 ±7
Rest of the population 432 (80%) 21 ±8
UCC, umbilical cord cyst; GA, gestational age; ANM, anorectal malformations; TOP, terminations of pregnancy; IUFD, 
intrauterine fetal death; eGFR, estimated glomerular filtration rate. 
Staging of LUtO 
The type of obstruction and the occasional development of pop-off mechanisms can 
partially account for the erratic variability in the clinical presentation of LUTO, that leads to a 
different timing and severity of urinary distension, oligohydramnios and renal impairment. 
Although the anatomical details of the urinary obstruction cannot be established during 
fetal life, their effects in term of urinary distension and progression to oligohydramnios can 
be more easily assessed. 
For this reason, in the last part of the thesis, we focused on a series of US parameters to 
predict perinatal mortality and postnatal renal function of LUTO (chapter 7 and 8). Figure 
3 summarizes our results in the form of a management algorithm, specifically formulated 
for male fetuses at high risk of LUTO, selected by following the two previous algorithms 
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(figure 1 and 2). However, it is probably essential to specify that female fetuses with LUTO 
are generally anyway excluded from fetal therapeutic interventions, since they almost 
invariably have a poor prognosis and extensive anomalies in the genitourinary region, 
including bowel, uterus and pelvic floor. 
In chapter 6, we have shown that the risk of perinatal mortality can be estimated by 
considering gestational age at first evidence of oligo- or anhydramnios, and the bladder 
volume at diagnosis. According to these two criteria, the severity of LUTO can be classified 
as severe, moderate of mild, entailing a perinatal mortality of 55%, 26% or 9%, respectively 
(chapter 7). 
Antenatal determination of renal injury in obstructive uropathy has been so far 
considered problematic (31). Previous observational studies reported that the accuracy of 
prenatal ultrasound for predicting renal function has low sensitivity and specificity (31)(32).
In chapter 5, we tried to elaborate a model based on prenatal US examination to predict 
postnatal renal function. We found that evidence of keyhole sign, hyperechogenicity of the 
renal cortex and abnormal amniotic fluid volume at diagnosis were associated with poor 
postnatal renal function (chapter 8). 
On the basis of the proposed staging system and the predicted postnatal renal function, 
the parents can be extensively counseled on the management options. In the majority of 
cases, parents will opt for terminating the pregnancy or for an expectative management 
(33)(4)(34). In a minority of cases, fetal intervention can be attempted. 
Management of LUtO
As discussed in the introduction of the thesis, the first antenatal therapeutically attempt 
for LUTO consisted in a bilateral utererostomies performed in open fetal surgery (35). This 
technique was promptly abandoned in favor of percutaneous vesico-amniotic shunting 
(VAS), that currently represents the most commonly used method to relieve the obstruction 
(36)(37). VAS has been widely used for at least 25 years and more than 300 cases of shunt-
treatment have been reported in the literature (37). During these years, different types of 
shunts have been developed, and a number of complications, such as shunt displacement, 
shunt blockage, preterm labor, chorio-amnionitis, iatrogenic gastroschisis and urinary 
ascites, have been reported (13).
Few studies have analyzed the pro and con of each shunt, therefore hereby, in table 2, we 








Weekly US for bladder and AF measurement 
+ estimate the prognosis 
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before 20 weeks 
Perinatal mortality: 55% 
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Estimate postnatal renal function by US scan + vesicocentesis 
and urine biochemistry + karyotype (if not already performed) 
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Poor renal function 
Early and late megacystis in male fetuses 
at risk of isolated LUTO 
Weekly US scan and consider 
amnioinfusions as experimental option 
Termination of 
pregnancy 
Deliver at a tertiary 
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Figure 3. Clinical algorithm to guide fetal specialists in the diagnostic work-up and management of 
male fetuses at risk of isolated LUTO.
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table 2. Characteristics of different catheter types used for VAS (38). 
Double-Pigtail Double-Basket
Characteristic Rocket Harrison Hakko
Diameter of device (F) 6.5 5 4.5
Diameter of coils-opened basket (mm) 18 NA 10
Length between both coils-baskets (mm) 3 1.5–3.5 2-3
Amniotic portion Double coil Double coil Basket
Intravesical portion 1.5 coil Single coil Basket
Double-pigtails catheters represent the classic choice. Two different types of double-pigtails 
catheters are available: Harrison type (Cook Medical, Bloomington, IN) and Rocket KCH one 
(Rocket Medical plc, Watford, England). The risk of shunt dislocations seems to be higher for 
the Harrison fetal bladder stent compared to the Rocket KCH fetal bladder catheter (78% 
vs 30%). Due to its smaller diameter, some clinicians prefer the Harrison catheter before 18 
weeks’ gestation (39)(40). A double-basket catheter has been more recently developed. This 
is a shunt with smaller diameter, therefore less invasive and with a lower risk of premature 
rupture of membranes (38). Despite the small diameter, the risk of occlusion seems 
comparable to that of the double-pigtail catheter, while the risk of dislocation seems to be 
higher (38). 
Fetal cystoscopy represents to date a promising alternative to VAS, although several 
technical difficulties still limit its use (13). In fact, in order to get a good visualization of 
the bladder neck, the scope would need to have a significant curve. Moreover, inserting 
the device in the dome of the bladder and manipulating it to enter the posterior urethra 
leads to leakage of urine into the abdominal cavity with subsequent loss of pressure in the 
bladder. For this reason, continuous fluid infusion and rapid performance of the procedure 
is needed. If the procedure fails to open the urethra, a shunt may be inserted through the 
cystoscope’s trocar, however the position of the shunt in the dome of the bladder is not ideal. 
Fetal cystoscopy allows to perforate the urethral valves by using hydroablation, guide-wire 
or laser fulguration and thus to restore the physiologic micturition (41)(42). Complications 
related to fetal cystoscopy are urethro-cutaneous or urethro-rectal fistulas, reported in 10% 
of treated fetuses (43). 
In our cohort, all fetuses were treated with VAS, with the use of the Rocket shunt, and 




Limitations and strength of this thesis. 
A number of potential limitations of this thesis needs to be acknowledged. Firstly, our results, 
except those from chapter 1, have been based on a retrospective study. The retrospective 
study design nature has limited the possibility to obtain specific measurements (such 
as urinary biochemistry, serial measurements, 3D bladder volume, echogenicity of renal 
parenchyma) in all cases. Despite this major limitation, the nationwide setting of this project 
constitutes a major strength of the thesis, and makes of this study the largest thus far 
published datasets on this topic. 
In this thesis, the bladder volume showed to have a central role for the diagnostic 
and prognostic assessment of megacystis and LUTO. Based on our results, we strongly 
recommended to incorporate the bladder measurement in the standard assessment of 
fetal megacystis and congenital LUTO. In the study the bladder volume was mathematically 
calculated from the three bladder diameters, rather than directly measured by the 3D US. 
This implied a bias due to the inaccuracy of the available formulas for measuring the fetal 
bladder (45)(46). We speculate that the bladder volume, measured by using 3D US, could 
have an even stronger prognostic and diagnostic value and future studies in this direction 
are needed. Moreover, for defining second and third trimester megacystis, we did not 
used a specific cut-off for the bladder enlargement but rather the most commonly used 
definition of a bladder failing to empty within 40 minutes. In fact, when our retrospective 
data collection was started, no reference range for defining an abnormally enlarged bladder 
was available. For this reason, we started to construct prospectively fetal bladder growth 
charts in Chapter 1.
Another crucial limitation of this study is the lack of an external validation for our proposed 
prediction models (chapter 5, 6 and 7). External validation is of paramount importance to 
judge the applicability of a prognostic model in a population outside the scope where the 
data have been derived from.
Future perspectives and challenges
Improvements in diagnostic accuracy of LUTO: Fetal MRI, grey-scale histogram, urine 
analysis and combined approaches.
In this thesis we relied upon clinical data from antenatal US investigations. However, further 
attention to other additional diagnostic tools should be paid. 
For instance, MRI, a technique increasingly used in fetal imaging (9)(8), may be explored 
for its value in assessing more accurately renal cortex integrity and lung development, 
as suggested by Craig Peters in a panel discussion at the Society of Fetal Urology (47). 
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Alternatively to the MRI, the use of grey-scale histogram may be tested for a more objective 
evaluation of the echogenicity of fetal renal parenchyma, which has proven to be, among all 
the other US parameters, the most reliable to predict postnatal renal function (32)(chapter 
8). 
To date, fetal urine analysis following serial vesicocentesis is standardly performed to 
estimate renal function before proceeding with any further intervention. Commonly, 
sodium, chloride, calcium, osmolarity and β2-microglobulin are evaluated, however data 
on their diagnostic ability are still conflicting (48)(49) and a systematic review reported that 
none of those analytes yields sufficient clinical accuracy for predicting renal function (48). 
Moreover, age-based reference ranges are to date available only for sodium and calcium 
(29), while the current established thresholds for the other analytes are only intended for 
fetuses undergoing fetal therapy (29). There has been an increasing interest in investigating 
a number of biochemical marker, such as α1-microglobulin, retinal binding protein, 
transforming growth factor-β, epidermal growth factor (29)(50), and more recently, the 
cystatine C and matrix metalloproteinase (MMP-9), independent predictors of severity of 
renal fibrosis. However, their clinical application has never been validated (31). 
Future studies are recommended to combine measurement of the above mentioned 
analytes with a more standardized US evaluation of LUTO.
Improvements in for future RCT: patient selection, data sharing and technical 
advancements.
At this moment to be able to identify the best candidates and timing for fetal therapy is 
of pivotal importance to improve clinical outcome in LUTO. The logic continuation of the 
studies published in this thesis will be to select cases by using our diagnostic and prognostic 
criteria and, according to the baseline LUTO severity, ascertain when fetal therapy would 
be more successful. We deliberately did not evaluate the success of fetal therapy in our 
cohort, due to the small sample of treated fetuses (n = 24). However, future investigations 
in this direction are recommended, preferably in the setting of an adequately powered 
randomized controlled trial. 
For this purpose, it must borne in mind that the low prevalence of LUTO and the high 
rate of terminations of pregnancy is likely to limit again the recruitment process, as it 
happened in the PLUTO trial (51). Therefore, more attention should also be paid on building 
large collaboration worldwide among the principal fetal surgery centers and on creating a 
more systematic approach to data sharing and frank disclosure of treatment failures. 
Besides the refinements of the diagnostic criteria and patient selection of LUTO, more 
effort should be aimed at improving in the technical aspects of the procedures, in terms of 
minimizing the risks of shunt migration and blockage in VAS and develop new cystoscopes 
capable of making easier the visualization and entrance into the posterior urethra (13). 
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9.8.3 Change of perspectives in fetal surgery. 
Classically, fetal surgery has been reserved to those fetuses with life-threatening conditions 
and few chances of survival (52). With technical advancements, antenatal surgery has been 
offered not only as ultimate attempt to rescue cases with otherwise fatal prognosis, but 
also to improve long-term outcome in fetuses with non-life-threatening conditions. This 
approach is now already used in the antenatal management of myelomeningocele. In fact, 
prenatal surgical repair of this non-lethal condition aims at improving the neurological 
outcome compared to the post-natal repair (53)(54). Similarly, also the TOTAL trial offers 
tracheal occlusion more liberally to diaphragmatic hernia cases at the less severe end of the 
spectrum in the attempt to improve long-term outcome (55). 
Concerning LUTO, fetal specialists still tend to treat cases with markedly reduced amniotic 
fluid and severe forms of LUTO. However, the severe deterioration of renal reserve among 
the severest phenotypes of LUTO may prevent an appropriate ‘rescue’ by fetal therapy. 
Conversely, the milder phenotypes may benefit more from fetal intervention (33). Timing is 
the central overarching theme in congenital LUTO and the best timing of in-utero therapy 
for preserving fetal renal function has not been yet clarified (26). 
Concluding remarks
We hope that the results of this thesis, with the proposed stepwise management algorithms, 
will contribute to refine the diagnostic work-up and the prognostic assessment of fetuses 
suspected with LUTO. We also hope that this may encourage a new trial where fetal surgery, 
in the form of refined shunts or cystoscopy, may be offered also to fetuses with good 
chances of survival but high risk of postnatal morbidity and renal insufficiency. This change 
in perspective is probably the necessary step in order to make an impact on the overall 
outcome of fetuses prenatally diagnosed with LUTO. 
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